Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis

Hepatology

Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis

J Hepatol.

Tapias EA, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, Graupera I, Brujats A, Vilades D, Colomo A, Poca M, Torras X, Guarner C, Concepción M, Aracil C, Torres F, Villanueva C

doi: 10.1016/j.jhep.2020.03.048.

Hepatology

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Lancet.

Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J

Hepatology

Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis

J Hepatol.

Turco L, Garcia-Tsao G, Magnani I, Bianchini M, Costetti M, Caporali C, Colopi S, Simonini E, De Maria N, Banchelli F, Rossi R, Villa E, Schepis F

doi: 10.1016/j.jhep.2017.12.027.

Hepatology

Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis

J Hepatol.

López-Vicario C, Checa A, Urdangarin A, Aguilar F, Alcaraz-Quiles J, Caraceni P, Amorós A, Pavesi M, Gómez-Cabrero D, Trebicka J, Oettl K, Moreau R, Planell N, Arroyo V, Wheelock CE, Clària J

doi: 10.1016/j.jhep.2020.03.046.

Further Publications

On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

J Hepatol

Caraceni P, Tufoni M, Zaccherini G, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Simone L, Svegliati-Baroni G, Fagiuoli S, Laffi G, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Gasbarrini A, De Marco R, Piano S, Nardelli S, Elia C, Roncadori A, Baldassarre M, Bernardi M, ANSWER Study Investigators.

doi: 10.1016/j.jhep.2020.08.021

Hepatology

Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis

Gastroenterology.

Intagliata NM, Caldwell SH, Tripodi A

doi: 10.1053/j.gastro.

Hepatology

The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis

J Hepatol

Arroyo V, Angeli P, Moreau R, Jalan R, Claria J, Trebicka J, Fernández J, Gustot T, Caraceni P, Bernardi M, investigators from the EASL-CLIF Consortium, Grifols Chair., European Foundation for the Study of Chronic Liver Failure (EFClif).

doi: 10.1016/j.jhep.2020.11.048

Hepatology

Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients

BMC Gastroenterol.

Hayashi T, Takatori H, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Shimakami T, Arai K, Kitamura K, Kawaguchi K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Toyama T, Okumura K, Kozaka K, Kaneko S

doi: 10.1186/s12876-019-1140-8.

Hepatitis

Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

J Hepatol.

Lens S, Baiges A, Alvarado E, LLop E, Martinez J, Fortea JI, Ibañez L, Mariño Z, Rodríguez-Tajes S, Gallego A, Bañares R, Puente Á, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, García-Pagán JC, Forns X

doi: 10.1016/j.jhep.2020.05.050.

Related content

Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis

Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis

On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis

The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis

Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients

Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension